CD44 and cancer: Although 21.7% of control CaSki cells were CD44+/CD24−, KIAA1199 deficiency dramatically decreased the pool of cancer stem cells as only 2.4% to 6.3% were CD44+/CD24−, depending on the efficiency of the shRNA-mediated depletion of KIAA1199 (Fig. 10f).